HOME >> MEDICINE >> NEWS
Pioglitazone shown to reverse thickening of carotid artery wall

Mainz, Germany, November 9, 2004 Clinical study results presented today in New Orleans, Louisiana, during the American Heart Association's Scientific Sessions 2004 proceedings, have shown that the drug pioglitazone (ACTOS, Takeda) significantly reduced the thickness of the carotid (neck) artery in patients with type 2 diabetes. By contrast, no change in carotid thickness was seen in a group of patients who received glimepiride, an older drug for type 2 diabetes.

"These results are provocative, because both drugs showed similar effects on lowering blood glucose, the traditional principal target for type 2 diabetes therapy," noted principal investigator Thomas Forst, Professor for Internal Medicine, Institute for Clinical Research and Development in Mainz, Germany.

"The thickness of the carotid artery is an indicator of atherosclerotic disease, which may both reduce arterial blood flow and set the stage for unstable blood clots in the arteries to dislodge and potentially cause a heart attack or stroke. The reduction in thickness by pioglitazone, a member of a new class of type 2 diabetes drugs called thiazolidinediones (TZDs) suggests that this medication may have benefits beyond improving metabolic control in patients with diabetes mellitus type 2," continued Forst. "This substantial regression of carotid intima media thickness over just 12 or 24 weeks may have important prognostic implications for patients with type 2 diabetes."

Study Design and Results

In the study, B-mode ultrasound was used to measure the intima media thickness (IMT) of the carotid artery before and 12 and 24 weeks after 173 patients received oral therapy with either pioglitazone (45 mg/day) or glimepiride (1-6 mg/day). Baseline carotid IMT was 0.949 0.149mm in the pioglitazone group and 0.924 0.150mm in the glimepiride group (p=n.s.). Carotid IMT was reduced only in the pioglitazone group after 12 weeks (-0.033 0.052mm) vs. -0.002 0.047mm
'"/>

Contact: Kate Sullivan
646-284-6514
Ketchum
9-Nov-2004


Page: 1 2

Related medicine news :

1. Pioglitazone HCI shown to lower blood pressure in hypertensive patients with type 2 diabetes
2. Cartilage repair techniques shown to restore patient mobility and reduce pain
3. Sprinklers shown effective in slowing dorm fires
4. Controversial drug shown to act on brain protein to cut alcohol use
5. HPV vaccine shown effective at reducing cancer-causing infections
6. HPV vaccine shown to substantially reduce cervical cancer
7. New research results: Heart jacket shown to be effective
8. Isolated soy protein shown to benefit type 2 diabetics, study indicates
9. Increased risk of cardiovascular disease shown in PCOS patients
10. Combination therapy w/ ACTOS (pioglitazone HCI) shown to improve components of diabetic dyslipidemia
11. Anti-eosinophil therapy shown to be effective in treating hypereosinophilic syndrome

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pioglitazone shown reverse thickening carotid artery wall

(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... Designers and Professionals of FCPX ... 5K from Pixel Film Studios. , “Scratches 5K allows ... inside Final Cut Pro X” Said Christina Austin, CEO ... is an effective tool for any FCPX editor.” , ... intuitive grunge overlays. Simply drag title layers into the ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Wellness for ... and business criteria for the spa and wellness industry–has ... clients who have experienced or are living with cancer. ... Spafinder Wellness 365® Network, will be identified with a ... as a provider of safe, therapeutic services for cancer ...
(Date:3/27/2015)... York (PRWEB) March 27, 2015 The ... ) that allege the statin medication increases the risk ... granted Pfizer Inc.’s Motion to Dismiss four individual cases ... a Case Management Order issued in the U.S. District ... Court determined that the dismissals were warranted because the ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
(Date:3/27/2015)... March 27, 2015 As of February, ... incontinence devices for women. "Shipping thousands ... gratifying part is the hundreds of letters, emails ... lives have been positively impacted by our technology," ... InControl recently released Apex, an over-the-counter ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
Cached News: